From July 15th to 17th, the 2019 National Pharmacy Week and China Pharmaceutical Innovation and Development Conference were grandly held in Jinan Shandong Building. At the meeting, five sub-lists including "Top 100 Chinese Chemical Pharmaceutical Enterprises" and "Top 100 Chinese Traditional Chinese Medicine Enterprises" of the "2018 Top 100 List of Chinese Pharmaceutical Industry" were announced, and Wanbangde Pharmaceutical Group was listed as "Top 100 Chinese Pharmaceutical Enterprises". Ranked 69th in the 2018 Top 100 Chinese Medicine Companies in China.

The list is organized by the Mine Research Institute of China's Top 100 Pharmaceutical Industry Ranking Expert Committee, relying on Minenet's database of three major terminals and six major market terminal patterns that has been developed and operated exclusively in China for many years, focusing on the two most important dimensions of innovation driving forces for pharmaceutical industry enterprises and professional promotion ability, after a comprehensive and objective and fair selection. Among them, the driving force of innovation is mainly judged from the comprehensive indicators of R&D investment of enterprises, and the professional promotion force is mainly defined according to the terminal quantitative data determined by the final selection needs of clinicians and patients.

After 17 years of development, Wanbangde Pharmaceutical Group has developed a large-scale R&D and industrialization centering on chemical and botanical drugs, and has formed a complete industrial chain from the production and supply of chemical raw materials and natural botanical raw materials to the production of finished preparations. In recent years, Wanbangde Pharmaceutical Group has adhered to the strategy of developing an enterprise through science and technology and strengthening its brand, and has achieved certain achievements in independent research and development of new products, training of innovative talents and R&D backbones, corporate profits and taxes, and quality construction. The group's business volume has grown steadily year by year, and its technological innovation capabilities have continued to make breakthroughs. It has created a number of well-known large varieties of traditional Chinese medicine, cultivated several single varieties, continued to expand the market size, and significantly improved its brand influence, winning wide praise from both inside and outside the industry.

Focusing on enhancing the independent innovation capability of enterprises, Wanbangde Pharmaceutical Group has integrated the scientific and technological innovation resources of more than ten scientific research institutes, hospitals and well-known universities at home and abroad, and established the "Ginkgo Leaf Dropping Pill Medical Research Enterprise Collaborative Innovation Alliance" led by Academician Wang Guangji. The second development of the core large variety Ginkgo Leaf Dropping Pill. The company's core product, Ginkgo Leaf Dropping Pill, has entered 9 clinical guidelines, expert consensus and clinical pathway interpretations, among which, as the only domestic oral ginkgo biloba variety, it has been included in the "Clinical Pathway Interpretation", involving diseases including transient ischemic attack, Interventional therapy for cerebral infarction, stable coronary heart disease and chronic stable angina pectoris, etc., as recommended drugs, were included in the "Chinese Expert Consensus on Diagnosis and Treatment of Cardiovascular Diseases with Insomnia", and included in the National Key Research Program in 2018 - a large variety of Chinese patent medicines registered in the EU The quality standard research variety (2018YFC1707905) has been rated as the national traditional Chinese medicine ingenuity product, the first batch of national high-quality Chinese patent medicine, and the first batch of Zhejiang famous medicine in 2019.

Wanbangde Pharmaceutical Group established a national model academician expert workstation led by Academician Tang Xican, and carried out the research and development of the anti-senile dementia drug Huperzine A raw materials and a series of preparations. Has successfully developed exclusive varieties of Huperzine A injection, new drug balanced salt flushing solution, Tongjingning granules and other products, and achieved industrial production.

In the next three years, Wanbangde Pharmaceutical Group plans to invest 1 billion yuan to build generic drug research and development, API and preparation production bases. Upgrade and develop new paths to promote high-quality development of enterprises.